Karvofil

Irbesartan, the active ingredient in Karvofil, is a angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It helps lower blood pressure and protects kidney function in certain patients, including those with diabetes.

GNH USA supplies Karvofil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin system to manage several cardiovascular and renal conditions. - Hypertension: reduces systolic and diastolic blood pressure, lowering cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Heart failure: improves symptoms and may reduce hospitalization when used as part of standard therapy.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Nasal congestion: blocked or runny nose. - Back pain: discomfort in the lower back region. - Upper respiratory infection: symptoms of a cold or mild flu.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring emergency care. - Hyperkalemia: elevated blood potassium that can affect heart rhythm. - Acute renal failure: sudden loss of kidney function. - Hepatic injury: abnormal liver enzymes or jaundice. - Severe hypotension: dangerously low blood pressure. - Neutropenia: low white‑blood‑cell count increasing infection risk.

Before initiating therapy, certain safety considerations are recommended. - Monitor blood pressure: ensure target levels are achieved without excessive drop. - Assess renal function: check serum creatinine and eGFR periodically. - Check serum potassium: avoid hyperkalemia, especially with potassium‑sparing agents. - Pregnancy caution: use only if benefits outweigh risks (Category D). - Contraindicated in bilateral renal artery stenosis: avoid to prevent renal ischemia. - Adjust in hepatic impairment: consider lower dose if liver disease is present. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Irbesartan may interact with several drug classes, influencing safety or efficacy.

Major Interactions (Avoid): - Aliskiren (in diabetes): combined use can increase renal dysfunction risk. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors: concurrent use raises risk of renal impairment and hyperkalemia. - NSAIDs: can reduce renal perfusion and worsen kidney function. - Lithium: may increase lithium serum concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Loop or thiazide diuretics: may enhance antihypertensive effect, requiring BP monitoring. - CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan levels. - Other antihypertensives: additive blood‑pressure lowering effect. - Rifampin: may lower irbesartan exposure, reducing efficacy. - Digoxin: monitor for signs of digoxin toxicity when combined with diuretics.